SRRK
Scholar Rock Holding Corporation NASDAQ Listed May 25, 2018$46.51
Mkt Cap $5.3B
52w Low $27.07
79.2% of range
52w High $51.62
50d MA $46.08
200d MA $40.24
P/E (TTM)
-14.1x
EV/EBITDA
-13.1x
P/B
21.7x
Debt/Equity
0.4x
ROE
-154.0%
P/FCF
-16.8x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$46.08
200d MA
$40.24
Avg Volume
1.5M
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
301 Binney Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 47.11 | +6.0% | -1.4% | — | — | — | — | — |
| Mar 3, 2026 | AMC | -0.88 | -0.88 | +0.3% | 44.31 | +3.3% | +7.0% | -2.7% | -1.9% | -2.3% | +1.2% | — |
| Nov 14, 2025 | AMC | -0.84 | -0.90 | -7.8% | 37.41 | -1.6% | -2.5% | +9.2% | -0.3% | -4.2% | +5.8% | — |
| Aug 6, 2025 | AMC | -0.66 | -0.98 | -48.5% | 34.62 | -0.0% | -9.3% | +1.8% | -1.6% | +2.4% | -0.7% | — |
| May 14, 2025 | AMC | -0.63 | -0.67 | -6.3% | 30.54 | +0.1% | +0.9% | -0.9% | -1.3% | +4.6% | -2.6% | — |
| Feb 27, 2025 | AMC | -0.60 | -0.60 | +0.0% | 35.96 | -0.7% | +8.0% | -6.7% | +2.4% | -2.6% | -0.0% | — |
| Nov 12, 2024 | AMC | -0.58 | -0.66 | -13.8% | 26.66 | +2.7% | +2.7% | +0.4% | -3.7% | -0.4% | +5.6% | — |
| Aug 8, 2024 | AMC | -0.61 | -0.60 | +1.6% | 8.17 | +1.6% | +3.4% | +12.2% | +2.4% | -5.1% | +1.8% | — |
| May 7, 2024 | AMC | -0.51 | -0.59 | -15.7% | 14.69 | -4.0% | -1.3% | +0.3% | -8.2% | +2.2% | +2.7% | — |
| Mar 19, 2024 | AMC | -0.49 | -0.50 | -2.0% | 15.15 | -1.1% | +8.6% | +4.6% | -4.7% | -2.3% | -6.3% | — |
| Nov 7, 2023 | AMC | -0.53 | -0.53 | +0.0% | 12.35 | +0.4% | -3.2% | -14.6% | -1.6% | -1.6% | +11.8% | — |
| Aug 9, 2023 | AMC | -0.56 | -0.47 | +16.1% | 6.09 | +3.1% | +11.3% | +4.0% | +1.0% | -3.1% | -3.8% | — |
| May 9, 2023 | AMC | -0.57 | -0.49 | +14.0% | 8.51 | +1.1% | -1.5% | -4.1% | -0.2% | +3.9% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Canaccord Genuity | Initiates | Buy | $62 | $47.80 | $48.00 | +0.4% | +0.6% | -1.6% | +0.3% | -2.1% | -0.4% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $49.16 | $49.88 | +1.5% | +0.4% | +1.3% | -2.4% | +2.2% | +0.2% |
| Mar 16 | JP Morgan | Maintains | Overweight → Overweight | — | $40.01 | $40.27 | +0.6% | +0.6% | +1.1% | -2.3% | +14.4% | -1.9% |
| Mar 4 | Truist | Maintains | Buy → Buy | — | $44.31 | $45.79 | +3.3% | +7.0% | -2.7% | -1.9% | -2.3% | +1.2% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $44.31 | $45.79 | +3.3% | +7.0% | -2.7% | -1.9% | -2.3% | +1.2% |
| Mar 4 | Barclays | Maintains | Overweight → Overweight | — | $44.31 | $45.79 | +3.3% | +7.0% | -2.7% | -1.9% | -2.3% | +1.2% |
| Mar 4 | Citigroup | Maintains | Buy → Buy | — | $44.31 | $45.79 | +3.3% | +7.0% | -2.7% | -1.9% | -2.3% | +1.2% |
| Mar 4 | BMO Capital | Maintains | Outperform → Outperform | — | $44.31 | $45.79 | +3.3% | +7.0% | -2.7% | -1.9% | -2.3% | +1.2% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.48 | $45.25 | +4.1% | +1.9% | +7.0% | -2.7% | -1.9% | -2.3% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.29 | $44.29 | +0.0% | +1.4% | -2.0% | -2.0% | +4.2% | -1.3% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $44.32 | $45.32 | +2.3% | -0.7% | -2.5% | +2.3% | +3.0% | +1.5% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $36.47 | $36.92 | +1.2% | +9.2% | -0.3% | -4.2% | +5.8% | +3.9% |
| Nov 17 | Barclays | Maintains | Overweight → Overweight | — | $37.41 | $36.81 | -1.6% | -2.5% | +9.2% | -0.3% | -4.2% | +5.8% |
| Oct 20 | Truist | Maintains | Buy → Buy | — | $27.94 | $28.17 | +0.8% | -0.1% | +0.9% | +1.2% | +0.5% | +3.6% |
| Sep 24 | Barclays | Maintains | Overweight → Overweight | — | $33.75 | $33.39 | -1.1% | -0.1% | +2.3% | +12.4% | -1.0% | -2.9% |
| Sep 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.75 | $33.39 | -1.1% | -0.1% | +2.3% | +12.4% | -1.0% | -2.9% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.58 | $29.90 | -8.2% | +3.6% | -0.1% | +2.3% | +12.4% | -1.0% |
| Aug 7 | BMO Capital | Maintains | Outperform → Outperform | — | $34.62 | $34.61 | -0.0% | -9.3% | +1.8% | -1.6% | +2.4% | -0.7% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.72 | $38.05 | +0.9% | -1.7% | +2.9% | +4.6% | -4.9% | +3.7% |
| Nov 25 | Truist | Maintains | Buy → Buy | — | $29.92 | $40.00 | +33.7% | +26.1% | -1.7% | +2.9% | +4.6% | -4.9% |
| Nov 25 | Wedbush | Maintains | Outperform → Outperform | — | $29.92 | $40.00 | +33.7% | +26.1% | -1.7% | +2.9% | +4.6% | -4.9% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.15 | $28.50 | +1.2% | -5.3% | +2.7% | +0.4% | -3.7% | -0.4% |
| Oct 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $28.52 | $28.93 | +1.4% | +0.1% | +1.6% | +0.9% | +4.4% | -1.9% |
| Oct 14 | JP Morgan | Maintains | Overweight → Overweight | — | $26.51 | $25.35 | -4.4% | +7.6% | +0.1% | +1.6% | +0.9% | +4.4% |
| Oct 11 | BMO Capital | Maintains | Outperform → Outperform | — | $26.14 | $25.37 | -2.9% | +1.4% | +7.6% | +0.1% | +1.6% | +0.9% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.28 | $33.09 | -3.5% | -14.0% | -5.8% | -5.9% | +1.4% | +7.6% |
| Oct 7 | Wedbush | Maintains | Outperform → Outperform | — | $7.42 | $26.34 | +255.0% | +362.0% | -14.0% | -5.8% | -5.9% | +1.4% |
| Oct 3 | JP Morgan | Maintains | Overweight → Overweight | — | $7.35 | $7.27 | -1.1% | -3.8% | +5.0% | +362.0% | -14.0% | -5.8% |
| Aug 9 | BMO Capital | Maintains | Outperform → Outperform | — | $8.17 | $8.30 | +1.6% | +3.4% | +12.2% | +2.4% | -5.1% | +1.8% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.41 | $8.37 | -0.5% | -4.0% | -2.9% | +6.6% | -0.4% | -2.4% |
| Jun 13 | BMO Capital | Maintains | Outperform → Outperform | — | $9.39 | $9.88 | +5.2% | +0.4% | +0.2% | -7.1% | -3.3% | -2.2% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.48 | $9.58 | +1.1% | +3.4% | +0.3% | -4.1% | +0.8% | +1.3% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.71 | $11.80 | +0.8% | -7.9% | -1.1% | -3.2% | -10.8% | +2.0% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.69 | $14.10 | -4.0% | -1.3% | +0.3% | -8.2% | +2.2% | +2.7% |
| Apr 3 | Truist | Maintains | Buy → Buy | — | $15.72 | $15.65 | -0.4% | -3.1% | -5.4% | -0.1% | +0.8% | +2.2% |
| Mar 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.01 | $16.23 | +1.4% | -6.3% | +3.0% | +15.0% | -5.5% | -6.4% |
| Mar 25 | Truist | Maintains | Buy → Buy | — | $16.39 | $16.18 | -1.3% | -2.3% | -6.3% | +3.0% | +15.0% | -5.5% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.20 | $12.81 | -3.0% | +14.8% | +8.6% | +4.6% | -4.7% | -2.3% |
| Oct 25 | Jefferies | Upgrade | Hold → Buy | — | $7.66 | $8.46 | +10.4% | +17.8% | +17.6% | -2.5% | +11.5% | +2.0% |
| Oct 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.85 | $7.73 | +12.8% | +17.7% | -2.7% | +5.4% | +5.3% | -13.6% |
| Aug 10 | Wedbush | Maintains | Outperform → Outperform | — | $6.09 | $6.28 | +3.1% | +11.3% | +4.0% | +1.0% | -3.1% | -3.8% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.09 | $6.28 | +3.1% | +11.3% | +4.0% | +1.0% | -3.1% | -3.8% |
| Jul 13 | Wedbush | Maintains | Outperform → Outperform | — | $7.00 | $6.99 | -0.1% | -0.4% | +0.7% | +3.0% | -0.3% | -1.4% |
| Jul 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.00 | $6.99 | -0.1% | -0.4% | +0.7% | +3.0% | -0.3% | -1.4% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.92 | $9.99 | +0.7% | +0.6% | -1.2% | -7.4% | +4.3% | +8.1% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $9.06 | $9.08 | +0.2% | -6.0% | -6.8% | +0.3% | -1.1% | +0.8% |
| Nov 15 | BMO Capital | Maintains | Outperform → Outperform | — | $8.59 | $8.90 | +3.6% | +9.8% | -4.0% | +0.1% | -6.0% | -6.8% |
| Aug 9 | BMO Capital | Maintains | Outperform → Outperform | — | $8.52 | $8.57 | +0.6% | +6.7% | +11.2% | +1.1% | +10.6% | -0.1% |
| Jul 12 | Truist | Maintains | Buy → Buy | — | $8.09 | $8.41 | +4.0% | -1.1% | +5.4% | -4.7% | -0.6% | -2.3% |
| Jun 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.46 | $5.35 | -2.0% | +14.1% | -4.3% | +23.2% | -21.5% | -5.9% |
No insider trades available.
8-K · 7.01
! Medium
Scholar Rock Holding Corporation -- 8-K 7.01: Regulation FD Disclosure
Scholar Rock will present Q1 2026 financial results and business updates via conference call on May 7, 2026 at 8:00 AM ET, with slides available for investor review.
May 7
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
The vague forward-looking statement language provides minimal concrete information about SRRK's actual business developments, leaving investors unable to assess material changes or upcoming catalysts affecting stock valuation.
Mar 31
8-K · 7.01
! Medium
Scholar Rock Holding Corporation -- 8-K 7.01: Regulation FD Disclosure
Scholar Rock Holding Corporation will host a March 3, 2026 earnings call to discuss full-year 2025 results and provide a business update via presentation slides.
Mar 3
8-K · 7.01
! Medium
Scholar Rock Holding Corporation -- 8-K 7.01: Regulation FD Disclosure
Scholar Rock (SRRK) will present 2025 financial results and business updates via conference call on March 3, 2026 at 8:15 am ET, with slides available for investors.
Mar 3
Data updated apr 27, 2026 2:51am
· Source: massive.com